Nurix Therapeutics (NRIX) Net Income towards Common Stockholders (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$89.5 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 106.0% year-over-year to -$89.5 million in Q2 2026; TTM through May 2026 was -$342.1 million, a 65.02% decrease from a year earlier, with the FY2025 full-year figure at -$264.5 million, down 36.62% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at -$89.5 million, down from -$87.9 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for NRIX reached as high as -$24.3 million in Q2 2023 and fell as low as -$89.5 million in Q2 2026.
• Historically, Net Income towards Common Stockholders has averaged -$53.3 million across 5 years, with a median of -$45.6 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders soared 46.53% in 2023 and sank 106.0% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$46.7 million in 2022, then grew by 10.19% to -$42.0 million in 2023, then sank by 39.55% to -$58.5 million in 2024, then tumbled by 33.6% to -$78.2 million in 2025, then retreated by 14.46% to -$89.5 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$89.5 million in Q2 2026, -$87.9 million in Q1 2026, and -$78.2 million in Q4 2025.